Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center.
Adult
Antiviral Agents
/ therapeutic use
Community Health Centers
/ organization & administration
Continuity of Patient Care
/ standards
Female
Hepatitis C, Chronic
/ drug therapy
Humans
Male
Massachusetts
Middle Aged
Shared Medical Appointments
/ organization & administration
Sustained Virologic Response
Treatment Outcome
Direct acting antiviral therapy
Hepatitis C
Peer support
Shared medical appointment
Task shifting
Journal
Journal of community health
ISSN: 1573-3610
Titre abrégé: J Community Health
Pays: Netherlands
ID NLM: 7600747
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
23
8
2018
medline:
15
2
2020
entrez:
23
8
2018
Statut:
ppublish
Résumé
Highly efficacious direct acting antiviral (DAA) therapy for treatment of Hepatitis C Virus (HCV) infection is largely inaccessible to communities facing a shortage of available specialist providers. Though less demanding than previous interferon regimens, DAA therapy requires patients to adhere to 8-12 weeks of daily treatment, which can be challenging for some patient populations. Duffy Health Center, located on Cape Cod, Massachusetts, provides integrated medical, mental health and case management services to people who are homeless or at risk for homelessness. The goal of this manuscript is to evaluate the outcomes of treatment of HCV infection with a shared medical appointment (SMA) model. The primary outcome was sustained virologic response (SVR-12), or HCV RNA ≤ 15 IU/mL at 12 weeks post-treatment. There were 102 patients recruited, with a total of 104 treatments administered. Over three-fourths of patients who attended one SMA visit (78 of 102) continued in SMA for the duration of treatment. Of these patients opting for SMA, 99% (77 of 78) completed the full treatment course, and 91% (71 of 78) of SMA patients achieved SVR-12. DAA therapy provided by non-specialist providers using the SMA model yielded comparable response rates to those achieved by specialist providers, and has the potential to substantially increase access to HCV treatment for patient populations within high-risk communities.
Identifiants
pubmed: 30132236
doi: 10.1007/s10900-018-0568-z
pii: 10.1007/s10900-018-0568-z
pmc: PMC6330118
mid: NIHMS994628
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-171Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002545
Pays : United States
Organisme : NIDA NIH HHS
ID : R25 DA037190
Pays : United States
Références
Am J Health Syst Pharm. 2016 Aug 1;73(15):1174-9
pubmed: 27440624
JAMA Intern Med. 2017 Jun 1;177(6):880-882
pubmed: 28395004
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
BMC Infect Dis. 2018 Feb 9;18(1):74
pubmed: 29426304
Ann Intern Med. 2017 Sep 5;167(5):311-318
pubmed: 28785771
BMJ. 2017 Aug 30;358:j4034
pubmed: 28855156
Am J Public Health. 2017 Jun;107(6):893-899
pubmed: 28426313
Hepatology. 2015 Nov;62(5):1353-63
pubmed: 26171595
PLoS One. 2015 Aug 27;10(8):e0135645
pubmed: 26312999
J Addict Med. 2018 Sep/Oct;12(5):346-352
pubmed: 29702515
J Clin Transl Hepatol. 2017 Jun 28;5(2):130-133
pubmed: 28660150